Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in ...

Fortuna Investments CEO Justus Parmar expects to see “a new vintage of space companies that hit the market” in 2025.

Karman Space and Defense ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, ...

Flowco Holdings Inc. ("Flowco"), a provider of production optimization, artificial lift and methane abatement solutions for ...

Evercore (NYSE:EVR) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ...

In a report released today, David Palmer from Evercore ISI maintained a Hold rating on Krispy Kreme (DNUT – Research Report), with a price target of $13.00. The company’s shares closed ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

Fintel reports that on January 7, 2025, Evercore ISI Group downgraded their outlook for Kraft Heinz (BRSE:KHC) from Outperform to In-Line. There are 2,025 funds or institutions reporting positions ...

Tidal Partners, a prominent player in mergers and acquisitions, recently announced the recruitment of investment banker Anand Sankaralingam from Evercore, according to confidential sources.